Raymond James Financial
PMVP icon

Raymond James Financial’s PMV Pharmaceuticals PMVP Stock Holding History

Raymond James Financial’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$212 – 6279
2025
Q2 		$212 Buy
+200
New +$196 ﹤0.01% 6775

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raymond James Financial's PMVP Position: Q3 2025 in Review

Raymond James Financial sold out of PMV Pharmaceuticals (PMVP) in Q3 2025, closing a stake of 200 shares — an estimated $212 sold.

Raymond James Financial first reported a position in PMVP in Q2 2025 and held it in 1 quarter. The position peaked at $212 in Q2 2025. 64 funds tracked by Wall St. Rank hold PMVP as of Q3 2025.

  • Raymond James Financial reported no remaining PMV Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 200 PMV Pharmaceuticals shares in Q3 2025, an estimated $212.
  • Raymond James Financial first reported a position in PMV Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's PMV Pharmaceuticals position peaked at $212 in Q2 2025.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.